Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Autolus Therapeutics Plc ADR (AUTL)

Autolus Therapeutics Plc ADR (AUTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Chart of the Day: Autolus Therapeutics - Effective Cancer Treatments

The Chart of the Day belongs to the oncology based biomedical company Autolus Therapeutics (AUTL) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical...

AUTL : 4.11 (+2.75%)
Autolus (AUTL) Selects Cardinal Health for Cell Therapy Supply

Autolus (AUTL) partners with Cardinal Health to bring next-generation CAR-T cell therapies to the market and revolutionize cancer treatment.

CAH : 102.98 (+0.79%)
OMCL : 29.29 (+7.80%)
SYNH : 42.98 (+0.02%)
AUTL : 4.11 (+2.75%)
Has Acasti Pharma (ACST) Outpaced Other Medical Stocks This Year?

Here is how Acasti Pharma (ACST) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.

ACST : 3.03 (+6.31%)
AUTL : 4.11 (+2.75%)
Is Alaunos Therapeutics (TCRT) Outperforming Other Medical Stocks This Year?

Here is how Alaunos (TCRT) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.

TCRT : 1.3600 (+5.43%)
AUTL : 4.11 (+2.75%)
Why Autolus Therapeutics Stock Is Crashing Today

Shares of Autolus Therapeutics (NASDAQ: AUTL) were crashing 35.9% as of 10:34 a.m. ET on Friday. The steep decline came after the biopharmaceutical company announced the price of a public stock offering...

AUTL : 4.11 (+2.75%)
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing

Palm Beach, FL – October 5, 2022 – FinancialNewsMedia.com News Commentary – Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting for up to 4% of all...

ONCY : 1.1700 (+4.46%)
ONC.TO : 1.59 (+3.25%)
SNTI : 0.3687 (-2.97%)
INBX : 34.01 (-0.85%)
IMVT : 28.78 (+0.91%)
AUTL : 4.11 (+2.75%)
BMY : 43.70 (-1.15%)
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting...

BMY : 43.70 (-1.15%)
ONC.TO : 1.59 (+3.25%)
ONCY : 1.1700 (+4.46%)
SNTI : 0.3687 (-2.97%)
INBX : 34.01 (-0.85%)
IMVT : 28.78 (+0.91%)
AUTL : 4.11 (+2.75%)
Correction - Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022

In the previous version the link to register for the conference call was incorrect – this press release contains the correct link to register for the call,...

AUTL : 4.11 (+2.75%)
Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022

LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation...

AUTL : 4.11 (+2.75%)
Autolus Therapeutics to Participate in William Blair’s Biotech Focus Conference 2022, New York, July 12 – 13, 2022

LONDON, July 06, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation...

AUTL : 4.11 (+2.75%)

Barchart Exclusives

3 Energy Dividend Stocks to Invest in Oil's 'Higher for Longer' Scenario
Discover how Schlumberger, Baker Hughes, and Halliburton are leveraging their robust financial health and strategic initiatives to thrive in a market where oil prices are expected to remain elevated, in our latest deep dive into the energy sector's top performers. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar